Cargando…
Inhaled antibodies: Quality and performance considerations
The use of antibodies in the treatment of lung diseases is of increasing interest especially as the search for COVID-19 therapies has unfolded. Historically, the use of antibody therapy was based on multiple targets including receptors involved in local hyper-reactivity in asthma, viruses and micro-...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116391/ https://www.ncbi.nlm.nih.gov/pubmed/34191682 http://dx.doi.org/10.1080/21645515.2021.1940650 |
_version_ | 1784710102912073728 |
---|---|
author | Hickey, Anthony James Stewart, Ian Edward |
author_facet | Hickey, Anthony James Stewart, Ian Edward |
author_sort | Hickey, Anthony James |
collection | PubMed |
description | The use of antibodies in the treatment of lung diseases is of increasing interest especially as the search for COVID-19 therapies has unfolded. Historically, the use of antibody therapy was based on multiple targets including receptors involved in local hyper-reactivity in asthma, viruses and micro-organisms involved in a variety of pulmonary infectious disease. Generally, protein therapeutics pose challenges with respect to formulation and delivery to retain activity and assure therapy. The specificity of antibodies amplifies the need for attention to molecular integrity not only in formulation but also during aerosol delivery for pulmonary administration. Drug product development can be viewed from considerations of route of administration, dosage form, quality, and performance measures. Nebulizers and dry powder inhalers have been used to deliver protein therapeutics and each has its advantages that should be matched to the needs of the drug and the disease. This review offers insight into quality and performance barriers and the opportunities that arise from meeting them effectively. |
format | Online Article Text |
id | pubmed-9116391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-91163912022-05-19 Inhaled antibodies: Quality and performance considerations Hickey, Anthony James Stewart, Ian Edward Hum Vaccin Immunother Passive SF – Reviews The use of antibodies in the treatment of lung diseases is of increasing interest especially as the search for COVID-19 therapies has unfolded. Historically, the use of antibody therapy was based on multiple targets including receptors involved in local hyper-reactivity in asthma, viruses and micro-organisms involved in a variety of pulmonary infectious disease. Generally, protein therapeutics pose challenges with respect to formulation and delivery to retain activity and assure therapy. The specificity of antibodies amplifies the need for attention to molecular integrity not only in formulation but also during aerosol delivery for pulmonary administration. Drug product development can be viewed from considerations of route of administration, dosage form, quality, and performance measures. Nebulizers and dry powder inhalers have been used to deliver protein therapeutics and each has its advantages that should be matched to the needs of the drug and the disease. This review offers insight into quality and performance barriers and the opportunities that arise from meeting them effectively. Taylor & Francis 2021-06-30 /pmc/articles/PMC9116391/ /pubmed/34191682 http://dx.doi.org/10.1080/21645515.2021.1940650 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Passive SF – Reviews Hickey, Anthony James Stewart, Ian Edward Inhaled antibodies: Quality and performance considerations |
title | Inhaled antibodies: Quality and performance considerations |
title_full | Inhaled antibodies: Quality and performance considerations |
title_fullStr | Inhaled antibodies: Quality and performance considerations |
title_full_unstemmed | Inhaled antibodies: Quality and performance considerations |
title_short | Inhaled antibodies: Quality and performance considerations |
title_sort | inhaled antibodies: quality and performance considerations |
topic | Passive SF – Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116391/ https://www.ncbi.nlm.nih.gov/pubmed/34191682 http://dx.doi.org/10.1080/21645515.2021.1940650 |
work_keys_str_mv | AT hickeyanthonyjames inhaledantibodiesqualityandperformanceconsiderations AT stewartianedward inhaledantibodiesqualityandperformanceconsiderations |